Distigmine

NERVOUS SYSTEM

Key facts

Distigmine is a drug catalogued in DrugCentral. It was first approved by the PMDA in 1967. DrugCentral lists 1 molecular target, including ACHE. Recorded indications include Acute cystitis, Difficulty passing urine and Myasthenia gravis.

• Molecular targets: ACHE (1 listed in DrugCentral).
• Indications: Acute cystitis, Difficulty passing urine and Myasthenia gravis.
• ATC code: N07AA03 (Anticholinesterases).
• Molecular formula: C22H32N4O4; molecular weight 416.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (3)

• Acute cystitis
• Difficulty passing urine
• Myasthenia gravis

Mechanism & targets

Molecular targets (1)

Target	Gene	Action	Activity
Acetylcholinesterase	ACHE	inhibitor	—

Regulatory approvals (1)

Date	Agency	Marketed as	Applicant	Orphan
1967-09-05	PMDA	—	Torii Pharmaceuticals

ATC classification

ATC code	Therapeutic hierarchy
N07AA03	NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Anticholinesterases

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Appendicolith	885.0
Appendicitis	741.9
Ventricular fibrillation	605.7
Cardiogenic shock	583.6
Blood phosphorus increased	563.1
Ascites	485.9
Stress	439.5
Multiple organ dysfunction syndrome	411.5
Myasthenia gravis	409.4
Abdominal distension	388.3
Blood uric acid increased	369.6
Hyponatraemia	352.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Distigmine is on its molecule page.

• Molecular formula: C₂₂H₃₂N₄O₄
• Molecular weight: 416.52 g/mol
• CAS number: 17299-00-2
• InChIKey: AHZBEVXBKNYXPU-UHFFFAOYSA-N
• PubChem CID: 3116

CN(CCCCCCN(C)C(=O)OC1=C[N+](C)=CC=C1)C(=O)OC1=C[N+](C)=CC=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Distigmine used for?

DrugCentral lists the following indications for Distigmine: Acute cystitis, Difficulty passing urine and Myasthenia gravis.

How does Distigmine work?

Its molecular targets in DrugCentral include ACHE (inhibitor).

When was Distigmine first approved?

Distigmine was first approved by the PMDA in 1967.

What is the chemical formula of Distigmine?

Distigmine has the molecular formula C22H32N4O4 and a molecular weight of 416.52 g/mol.

Sources

• DrugCentral drug card 927 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL1098285 — compound record and bioactivity
• PubChem CID 3116 — chemical identifiers
• DrugBank DB13694 — drug record
• FDA UNII T940307O7B — substance identity
• UniProt P22303 (ACHE) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral

How this page is built: methodology · editorial policy & corrections.